Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Vedolizumab for Collagenous Colitis: Medical Necessity Assessment

Introduction to Vedolizumab

  • Vedolizumab is FDA-approved for moderate to severe ulcerative colitis and Crohn's disease, but not for microscopic colitis subtypes including collagenous colitis 1, 2
  • The British Society of Gastroenterology guidelines (2025) do not include vedolizumab as a recommended treatment for microscopic colitis subtypes 1, 2

Patient Evaluation and Treatment

  • The patient has negative TB testing, which would be required if biologic therapy were to be considered 3, 4
  • The proposed vedolizumab dosing regimen (300mg at weeks 0, 2, 6, then every 8 weeks) is the standard dosing for approved indications, but not validated for collagenous colitis 5, 6